openPR Logo
Press release

SMR Adalimumab Market Value Share, Supply Demand, share and Value Chain 2014-2020

06-27-2016 11:33 AM CET | Industry, Real Estate & Construction

Press release from: SyndicateMarketResearch

SMR Adalimumab Market Value Share, Supply Demand, share

Adalimumab is a biologic TNF inhibiting anti-inflammatory medication which is a patented medicine of Abbott Biotechnology Ltd. Jochen G. Salfeld et al invented the product and trade names for the product are Exemptia and Humira. Humira stands for "human monoclonal antibody in rheumatoid arthritis". Humira targets and acts as building block for TNF-alpha production, and lowering inflammation. TNF blockers with HUMIRA, has adverse affects on the immune system which is a serious side effect of this medicine. Adalimumab is prescribed for Crohn’s disease, Rheumatoid arthritis, ulcerative colitis and psoriasis disorders. PsA leads to excess production of definite proteins, and people with PsA, TNF causes swelling in joints.

Increasing number of female populace is becoming susceptible to arthritis due to loss of body calcium. Rising occurrence of arthritis is a main driver for the growth of the adalimumab market. Enhanced analysis rate along with the introduction of proficient biologic drugs are also some of the major factors to support the market growth. Additional, growing deskbound routine is boosting the prevalence of arthritis commonness. On the other side, high price and low openness are the foremost factor restricting the escalation of the global adalimumab market.

Browse the “Adalimumab Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” fullreport at http://www.syndicatemarketresearch.com/market-analysis/adalimumab-market-global-industry-analysis-size-share-growth.html

The report covers forecast and analysis for the adalimumab market on a global and regional level. The study provides significant data of 2014 along with estimated from 2014 to 2020 based on revenue (USD Million). The report also offers detailed competitive landscape of the global adalimumab market. It includes company market share analysis, product portfolio of the major industry participants. The report provides detailed segmentation of the biomarker technologies market based on application segment and region.

The global adalimumab market is segmented on basis of applications and regions. The application part is diverged into, psoriasis, ulcerative colitis, rheumatoid arthritis, Crohn's disease and others.

Get saple research report athttp://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=60775

Geographically, adalimumab market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, further bifurcation of region on the country level, which include U.S., Canada, Germany, Italy, France, Spain, China, India, Australia, New Zealand and of Asia Pacific. Currently, North America and Europe are dominating the global adalimumab market. Factors such as controlled authoritarian structure, sophisticated healthcare infrastructure are pouring the adalimumab market in North America and Europe market. Asia Pacific adalimumab market is predicted for significant growth in future, rapidly rising healthcare, increasing disposable income and supportive government initiatives to reinforce healthcare division in various countries are escalating the adalimumab market in Asia Pacific. High geriatric population in the economies such as India and China is projected to stimulate the demand for arthritis curing drugs.

Adalimumab commonly utilized in developed countries as compared to other and hence market is impacted by the existence of regional players

Amgen, Mylan N.V., Pfizer, AbbVie, Boehringer Ingelheim GmbH, Mylan N.V. and Novartis AG comprise some of the players in adalimumab market.

The report segments the adalimumab market into:

Adalimumab Market: Application Segment Analysis

Get saple research report athttp://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=60775

Psoriasis
Ulcerative colitis
Rheumatoid arthritis
Crohn's disease
Others
Adalimumab Market: Regional Segment Analysis

North America
U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East & Africa
Browse the “Adalimumab Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” fullreport at http://www.syndicatemarketresearch.com/market-analysis/adalimumab-market-global-industry-analysis-size-share-growth.html

Contact US:

Joel John
3422 SW 15 Street,Suit #8138
Deerfield Beach,Florida 33442
United States

Toll Free: +1-855-465-4651 (USA-CANADA)
Tel: +1-386-310-3803
Email:sales@SyndicateMarketResearch.com

Website http://www.syndicatemarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SMR Adalimumab Market Value Share, Supply Demand, share and Value Chain 2014-2020 here

News-ID: 345991 • Views: 706

More Releases from SyndicateMarketResearch

Drill Bits Market: Segment and Analysis up to 2015 – 2020
Drill bits machine are cutting tools used to remove material to create holes, always of circular cross-section. Drill bit is a tool designed to create a cylindrical hole in the earth’s crust by the rotary drilling machine method for the extraction of hydrocarbon such as natural gas, petroleum, and crude oil. Drill bits are mainly classified into two types such as rolling cutter and fixed cutter bits. The structure of
Smart Transformers Market: Segment and Analysis up to 2015 – 2020
Smart transformer is also known as solid state transformer. Smart transformer controls power distribution networks. It makes possible the conversion of AC to DC and DC to AC, as per requirement. Smart transformer (ST) provides the exact amount of power that is needed, and responds instantly to fluctuations within the power grid, acting as a voltage regulator to ensure that the optimized voltage is undisturbed. Smart transformer facilitates appliances to
Liquefied Petroleum Gas (LPG) Market – reports,2015 – 2021
Liquefied petroleum gas (LPG) is a combustible mix of hydrocarbon gases. LPG is directed as fuel in heating appliances, vehicles, aerosol propellant, refrigerant and cooking equipment, etc. LPG is also referred as propane or butane. LPG offers several benefits such as low cost, low carbon emission and other operational benefits. LPG can be employed as a feedstock in petrochemical and refinery complexes and usually used as substitute to naphtha. Get a
Petroleum Coke Market Segment and Analysis up to 2015 – 2021
Petroleum coke is valuable consumer products derived from oil refining process. Petroleum coke is also known as pet coke. The crude oil residue further refined by a process known as coking to produce pet coke. Petroleum coke has highest carbon purity and is used in energy and in the aluminum, graphite electrode, steel, titanium dioxide and other carbon consuming industries. Petroleum coke can resemble small spheres, ranging in size from

All 5 Releases


More Releases for Adalimumab

Pipeline Analysis: LATAM Adalimumab Market
The Latin America (LATAM) adalimumab market features the dominance of few companies operating amid a lackluster market, a limited set of growth opportunities, and the looming threat of biosimilars, observes Transparency Market Research in a report. The drug being a biologic, carries a high price tag, making it difficult for the largely cost-conscious consumers in the region to procure it. The presence of several biosimilars and the projected introduction of
10-11-2017 | Health & Medicine
TMR
LATAM Adalimumab Market – Global Industry Analysis 2015
The Latin America (LATAM) adalimumab market features the dominance of few companies operating amid a lackluster market, a limited set of growth opportunities, and the looming threat of biosimilars, observes Transparency Market Research in a report. The drug being a biologic, carries a high price tag, making it difficult for the largely cost-conscious consumers in the region to procure it. The presence of several biosimilars and the projected introduction of several new
Adalimumab Biosimilar Market 2017 - AET BioTech, Amgen, Boehringer Ingelheim
Apex Research, recently published a detailed market research study focused on the "Adalimumab Biosimilar Market" across the global, regional and country level. The report provides 360° analysis of "Adalimumab Biosimilar Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Adalimumab Biosimilar industry, and estimates the future trend of Adalimumab Biosimilar market on
Adalimumab Market Size, Status & Forecast 2024
Global Adalimumab Market: Overview Adalimumab, with a trade name of Humira and Exemptia, is an anti-TNF drug used for treating rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and ulcerative colitis. Adalimumab usually binds with tumor necrosis factor-alpha (TNFα). When a TNFα binds to a TBFα receptors, it results in an inflammatory response to autoimmune disease. Adalimumab, by binding to a TNFα, lowers the chances of inflammatory response. View Report @ http://www.transparencymarketresearch.com/adalimumab-market.html Adalimumab, which
Adalimumab Market - Forecasts from 2014 to 2020
Adalimumab is a biologic TNF inhibiting anti-inflammatory medication which is a patented medicine of Abbott Biotechnology Ltd. Jochen G. Salfeld et al invented the product and trade names for the product are Exemptia and Humira. Humira stands for "human monoclonal antibody in rheumatoid arthritis". Humira targets and acts as building block for TNF-alpha production, and lowering inflammation. TNF blockers with HUMIRA, has adverse affects on the immune system which
Increasing Research and Penetration of Adalimumab Biosimilars Boosts Demand for …
The impending patent expiration has resulted in the sluggish growth rate of the adalimumab market in Latin America. The entry of biosimilars has further aggravated the market’s concerns. Transparency Market Research (TMR) pegs the valuation of the Latin America adalimumab market at US$994.8 mn in 2014. Expanding at a weak CAGR of 0.4% from 2015 to 2023, the market is forecast to reach US$1,186.4 mn by the end of 2023. Download